Search research articles
Contact Us
Filters
Showing results (11-20 of 96) with videos related to
Page
of 10
Sort By:
Therapeutic Advances in Medical Oncology
|
March 14, 2020
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors
Zoé Neviere, Thibault De La Motte Rouge, Anne Floquet, et al.
Bulletin Du Cancer
|
June 20, 2017
Anne Floquet, Dominique Berton-Rigaud, Gwenael Ferron, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
August 13, 2011
Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?
Eberhard Stoeckle, Benjamin Boubli, Anne Floquet, et al.
Oncology
|
November 27, 2009
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Marc Debled, Nicolas Madranges, Alexandra Trainaud, et al.
Brachytherapy
|
July 25, 2013
Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution
Adeline Petit, Anne Floquet, Olivier Lasbareilles, et al.
Bulletin Du Cancer
|
February 22, 2014
[Hereditary ovarian carcinomas: clinico-biological features and treatment]
Anne Floquet, Eberhard Stoeckle, Sabrina Croce, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 30, 2021
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol
Stamatios Petousis, Sabrina Croce, Michel Kind, et al.
Diagnostic and Interventional Imaging
|
June 11, 2021
Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy
Amandine Crombé, Lisa Gauquelin, Stéphanie Nougaret, et al.
Plos One
|
July 7, 2012
MED12 alterations in both human benign and malignant uterine soft tissue tumors
Gaëlle Pérot, Sabrina Croce, Agnès Ribeiro, et al.
Investigational New Drugs
|
November 6, 2004
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
Francesco Caponigro, Pax Willemse, Roberto Sorio, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 96) with videos related to
Sort By:
Page
of 10
Therapeutic Advances in Medical Oncology
|
March 14, 2020
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors
Zoé Neviere, Thibault De La Motte Rouge, Anne Floquet, et al.
Bulletin Du Cancer
|
June 20, 2017
Anne Floquet, Dominique Berton-Rigaud, Gwenael Ferron, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
August 13, 2011
Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?
Eberhard Stoeckle, Benjamin Boubli, Anne Floquet, et al.
Oncology
|
November 27, 2009
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Marc Debled, Nicolas Madranges, Alexandra Trainaud, et al.
Brachytherapy
|
July 25, 2013
Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution
Adeline Petit, Anne Floquet, Olivier Lasbareilles, et al.
Bulletin Du Cancer
|
February 22, 2014
[Hereditary ovarian carcinomas: clinico-biological features and treatment]
Anne Floquet, Eberhard Stoeckle, Sabrina Croce, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 30, 2021
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol
Stamatios Petousis, Sabrina Croce, Michel Kind, et al.
Diagnostic and Interventional Imaging
|
June 11, 2021
Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy
Amandine Crombé, Lisa Gauquelin, Stéphanie Nougaret, et al.
Plos One
|
July 7, 2012
MED12 alterations in both human benign and malignant uterine soft tissue tumors
Gaëlle Pérot, Sabrina Croce, Agnès Ribeiro, et al.
Investigational New Drugs
|
November 6, 2004
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
Francesco Caponigro, Pax Willemse, Roberto Sorio, et al.
Page
of 10